Clinical Trials Browser

Active not recruiting × Brentuximab Vedotin × 1 year × Clear all

NCT03907488 2026-06-01

Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III-IV Classic Hodgkin Lymphoma

Phase 3 Active not recruiting

994 enrolled 11 charts 1 FDA

Hodgkin Disease

NCT01703949 2026-05-12

Brentuximab Vedotin With or Without Nivolumab in Treating Patients With Relapsed or Refractory CD30+ Lymphoma

Phase 2 Active not recruiting

28 enrolled 11 charts

Hodgkin Disease, Lymphoma, Non-Hodgkin

NCT01920932 2026-05-06

Adcetris (Brentuximab Vedotin), Combination Chemotherapy, and Radiation Therapy in Treating Younger Patients With Stage IIB, IIIB and IV Hodgkin Lymphoma

Phase 2 Active not recruiting

77 enrolled 20 charts

Hodgkin Disease, Neoplasms

NCT03057795 2026-05-01

Nivolumab & Brentuximab Vedotin Consolidation After Autologous SCT in Patients With High-Risk Classical Hodgkin Lymphoma

Phase 2 Active not recruiting

62 enrolled 8 charts

Hodgkin Disease

NCT03755804 2026-04-23

Pediatric Classical Hodgkin Lymphoma Consortium Study: cHOD17

Phase 2 Active not recruiting

Hodgkin Disease, Neoplasms

NCT04404283 2026-04-20

ECHELON-3

Phase 3 Active not recruiting

239 enrolled 1 FDA

Lymphoma, Large B-Cell, Diffuse

NCT05922904 2026-04-15

PET Adapted Brentuximab Vedotin and Pembrolizumab in Combination With Doxorubicin and Dacarbazine in Classic Hodgkin Lymphoma

Phase 2 Active not recruiting

Hodgkin Disease

NCT01352520 2026-01-20

SGN-35 in CD30-positive Lymphoproliferative Disorders (ALCL), Mycosis Fungoides (MF), and Extensive Lymphomatoid Papulosis (LyP)

Phase 2 Active not recruiting

DermatologicLymphoid

Hematologic Diseases, Lymphoma, Mycosis Fungoides, Lymphoma, T-Cell, Cutaneous, Lymphomatoid Papulosis, Lymphoma, Primary Cutaneous Anaplastic Large Cell

NCT03113500 2025-11-14

Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With CD30-Positive Peripheral T-cell Lymphoma

Phase 2 Active not recruiting

48 enrolled 8 charts

LymphoidOther hematologic neoplasm

Immunoblastic Lymphadenopathy, Lymphoma, T-Cell, Lymphoma, Large-Cell, Anaplastic, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, Enteropathy-Associated T-Cell Lymphoma

NCT02979522 2025-11-10

A Study of Brentuximab Vedotin + Adriamycin, Vinblastine, and Dacarbazine in Pediatric Participants With Advanced Stage Newly Diagnosed Hodgkin Lymphoma

Phase 1/2 Active not recruiting

59 enrolled 63 charts

Hodgkin Disease

NCT02734771 2025-08-12

BV mini CHP

Phase 2 Active not recruiting

Lymphoma, Large B-Cell, Diffuse

NCT05673785 2025-07-14

A Study of Brentuximab Vedotin in Combination With Cyclophosphamide, Doxorubicin (Hydroxydaunorubicin), Prednisone (CHP) in Chinese Participants With CD30-Positive (CD30+) Peripheral T-Cell Lymphomas (PTCL)

Phase 2 Active not recruiting

Lymphoma